Table 1.
Baseline characteristics of both patients undergoing index versus repeat ablation
| Index (n = 3377) | Repeat (n = 738) | Odds ratio (95%-CI) or p-value | |
|---|---|---|---|
| Age (years) | 62 (54; 68) | 63 (55; 68) | P = 0.69 |
| Female sex | 33.5% | 29.1% | 1.23 (1.03–1.46) |
| Diabetes mellitus | 7.8% | 6.8% | 1.17 (0.86–1.60) |
| Chronic kidney disease | 2.1% | 2.8% | 0.76 (0.21–2.72) |
| Hypertension | 61.1% | 64.5% | 0.86 (0.56–1.32) |
| Stroke | 5.6% | 4.6% | 1.24 (0.47–3.26) |
| COPD | 1.2% | 2.8% | 0.44 (0.11–1.73) |
| Cardiac device (PM, ICD, CRT) | 5.9% | 6.2% | 0.95 (0.68–1.32) |
| Pacemaker | 4.4% | 5.3% | 1.20 (0.84 -1.72) |
| ICD | 1.4% | 0.9% | 0.66 (0.30–1.47) |
| CRT | 0.1% | 0.1% | 2.29 (0.21–25.28) |
| Coronary artery disease | 18.2% | 16.1% | 1.15 (0.93–1.43) |
| Prior myocardial infarction | 4.6% | 6.2% | 0.73 (0.52–1.03) |
| Cardiomyopathy (HCM, DCM) | 3.9% | 3.8% | 1.04 (0.69–1.58) |
| Valvular heart disease | 6.6% | 9.1% | 0.70 (0.53–0.94) |
| LVEF preserved (> 50%) | 86.8% | 88.0% | 0.90 (0.69–1.17) |
| CHA2DS2-VASc Score | 1.8 ± 1.3 | 1.7 ± 1.2 | P = 0.63 |
| NYHA 2 + | 39.7% | 49.4% | 0.67 (0.51–0.88) |
| Atrial fibrillation type | |||
| Paroxysmal | 69.3% | 61.9% | P < 0.001 |
| Persistent | 30.7% | 38.1% | P < 0.001 |
All values given as percentages or mean with standard deviation or quartiles. P value < 0.05 was considered significant
CI confidence interval, COPD Chronic Obstructive Pulmonary Disease; PM Pacemaker; ICD Implantable Cardioverter Defibrillator; CRT Cardiac Resynchronization Therapy; HCM Hypertrophic Cardiomyopathy; DCM Dilatative Cardiomyopathy; LVEF Left-Ventricular Ejection Fraction; NYHA New York Heart Association